EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies

Birgitte S Wulff iD, Adam Paul Chambers, Cynthia Karenina Osorto Contreras, Katrine Kirkeby iD, Anders Rasmussen Rinnov iD, Riia K Sustarsic iD, Søren Østergaard iD, John E Laabs, Patrick M O'Neil iD

Obesity · 2025

DOI: 10.1002/oby.24329 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Obesity, 2025. Verfasst von Birgitte S Wulff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Måløv, Denmark. Hauptthemen laut MEDLINE: Peptide YY, Obesity, Glucagon-Like Peptides, Peptide Fragments. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The hormone peptide YY (PYY; cleaved into Y 2 ‐selective form PYY 3‐36 ) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This series of studies investigated a novel long‐acting PYY 3‐36 analogue (PYY1875) alone and as an add‐on to semaglutide for treatment of obesity.

Methods

Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.

Results

PYY1875 induced additional body weight loss in semaglutide‐treated obese rats. In the phase 1 study, all doses of PYY1875 alone and coadministered with semaglutide were tolerated. In the phase 2 study, a modest but not clinically meaningful treatment effect of PYY1875 1.0 mg versus placebo as an add‐on to semaglutide 2.4 mg was observed. However, gastrointestinal‐related adverse events were common with the 1.0‐mg PYY1875 dose, and the 2.0‐mg PYY1875 dose escalation regimen was not tolerated (both as add‐ons to semaglutide).

Conclusions

PYY1875 showed modest efficacy as an add‐on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide YYObesityGlucagon-Like PeptidesPeptide FragmentsAnti-Obesity AgentsMaleAnimalsHumansRatsAdultMiddle AgedWeight LossFemaleDrug Therapy, CombinationDouble-Blind MethodEatingGlucagon-Like Peptide 1Semaglutide

Substanzen

Peptide YYGlucagon-Like PeptidesPeptide FragmentsAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutidepeptide YY (3-36)

Autor:innen und Institutionen

  • Novo Nordisk A/S, Måløv, Denmark.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Celerion, Tempe, Arizona, USA.
  • Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID-Profile: Birgitte S Wulff, Katrine Kirkeby, Anders Rasmussen Rinnov, Riia K Sustarsic, Søren Østergaard, Patrick M O'Neil

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Wulff, B. S., Chambers, A. P., Osorto Contreras, C. K., Kirkeby, K., Rinnov, A. R., Sustarsic, R. K., Østergaard, S., Laabs, J. E., & O'Neil, P. M. (2025). Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies. Obesity. https://doi.org/10.1002/oby.24329

Vancouver

Wulff BS, Chambers AP, Osorto Contreras CK, Kirkeby K, Rinnov AR, Sustarsic RK, et al. Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies. Obesity. 2025. doi:10.1002/oby.24329

BibTeX
@article{Wulff2025,
  author = {Wulff, Birgitte S and Chambers, Adam Paul and Osorto Contreras, Cynthia Karenina and Kirkeby, Katrine and Rinnov, Anders Rasmussen and Sustarsic, Riia K and Østergaard, Søren and Laabs, John E and O'Neil, Patrick M},
  title = {Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies},
  journal = {Obesity},
  year = {2025},
  doi = {10.1002/oby.24329}
}
Kostenlos starten →